• Anticancer therapy at end-of-life: A retrospective cohort study 

      Singh, Johnny Joginder; Stensvold, Andreas; Turzer, Martin; Grov, Ellen Karine (Peer reviewed; Journal article, 2024)
      Background: A significant proportion of patients with incurable cancer receive systemic anticancer therapy (SACT) within their last 30 days of life (DOL). The treatment has questionable benefit, nevertheless is considered ...
    • Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable 

      Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Kolstad, Arne; Stokke, Caroline (Acta Oncologica;Volume 60, 2021 - Issue 11, Peer reviewed; Journal article, 2021-08-23)
      Background: The aim of this study was to investigate dosimetry data and clinical variables to predict hematological toxicity in non-Hodgkin lymphoma (NHL) patients treated with [177Lutetium]Lu-liloto-mab satetraxetan. Material ...
    • Thyroid hypofunction in aging testicular cancer survivors 

      Nome, Ragnhild V.; Småstuen, Milada Cvancarova; Fosså, Sophie D.; Kiserud, Cecilie E.; Åsvold, Bjørn Olav; Bjøro, Trine (Peer reviewed; Journal article, 2021)
      Purpose Thyroid hypofunction is a late effect observed in several groups of cancer survivors, but has to date not been evaluated in-depth in testicular cancer survivors (TCSs). We investigated the prevalence of thyroid ...